Alzheimer’s Treatment Centers of America (ATCA) tackles one of the most heart-wrenching challenges families face. Alzheimer’s disease degenerates loved ones in three main areas: memory, cognition, and motor skills. This causes memory loss, mood changes, difficulty speaking, swallowing, walking and eventually death. In the documented 2 ½ year trial using our patented protocol: up to 76% of the patients either had no further decline or, even better, had improvement in their mild cognitive impairment.

The Most Comprehensive Approach to Personalized Alzheimer’s Therapy

Caring for a family member with Alzheimer’s can be extremely challenging, and despite a significant amount of research and clinical trials in the area, there is yet no Alzheimer’s cure. The Alzheimer’s Treatment Centers of America is committed to furthering a personalized approach to Alzheimer’s care, offering access to a proprietary combination of treatment modalities that are designed to increase quality of life. Our patented approach is more effective than the leading pharmaceutical options.

The Challenges in Treating Alzheimer’s Patients

Alzheimer’s is not a simple disease, and patients usually suffer from a number of additional comorbidities. While current clinical research focuses on identifying a single treatment, the reality is that patients require individualized treatment depending on their overall health, stage of disease and other risk factors. Our solution takes into account all of these factors and provides a strong foundation for effective treatment.

Taking an Individualized Approach to Alzheimer’s Care

Our patented protocol involves a range of techniques to provide the right kind of treatment approach for each individual patient. We utilize an innovative process that uses artificial intelligence combined with genetic testing, medicine, behavioral-based design and more to successfully halt the progression of Alzheimer’s and even reverse the effects in a larger cohort of patients. This data-driven approach is only offered by Alzheimer’s Treatment Centers of America through our proprietary solution.

Improving the Lives of American Families

The Alzheimer’s Treatment Centers of America is committed to improving the life of Alzheimer’s patients and their families across the entire country using personalized approaches that treat the individual. In the documented 2½ year trial using our patented protocol, we observed up to 76% of the patients either had no further decline or, even better, had improvement in their mild cognitive impairment. To learn more about our approach, contact our team today at (404) 999-2605.

  • For the families involved, they eventually may not be recognized by their loved ones. For them, the disease can create a huge time burden, guilt, grief, loss, financial burden, frustration, and overwhelming sadness.
  • Dauntingly, Alzheimer’s is both widespread and growing. One in three seniors die with Alzheimer’s. 5.8 Million Americans have been diagnosed with Alzheimer’s, and is growing 3.5% per year. Moreover, another 16 Million unpaid family members struggle as caregivers of Alzheimer’s patients2.
  • Based on forward projections, our solution has the opportunity to directly delay the onset of 4.3M estimated new cases of Alzheimer’s between now and 2025.
  • Alzheimer’s costs $290 Billion in just the USA and is growing rapidly. Working with our patented product the key factor is to ramp up distribution of our leading solution to help more people.

Alzheimer’s is a complicated thing to “solve.” Alzheimer’s patients have 5 or more other chronic conditions over 25% of the time, on top of having Alzheimer’s (and most likely related to overall body imbalance).

Virtually all Alzheimer’s drugs are looking for the silver bullet- a single pronged approach. We believe that philosophy is fundamentally flawed, and that Alzheimer’s is a multi-faceted, multifactorial issue. For that reason, there hasn’t been a new solution to improve upon Alzheimer’s treatments in over 15 years, until now.



  • Alzheimer’s disease is a progressive, inexorable loss of cognitive function. The underlying pathogenesis is a loss of neurons in the hippocampus, cortex, and subcortical structures of the brain. The disease is the most common form of dementing illness among middle-aged and older adults. Symptoms typically appear after age 60, although some early-onset forms of the disease are linked to specific genetic defects. Although the etiology is unknown, genetic factors play a role in 10% to 15% of cases.
  • Early disease shows a loss of short-term memory, inability to learn new information, mood swings, difficulty in finding words, forgetting names, and losing items. Frustration, hostility, and irritability are common emotional features exhibited by patients with Alzheimer’s disease.
  • As the disease progresses, patients become incontinent, memory is lost, and sense of time and place disappears. Patients become dependent upon others and eventually require comprehensive care. Because of a patient’s total dependency upon others, placement in a nursing home with full-time nursing care becomes necessary. Thus, Alzheimer’s disease presents a considerable problem in patient management, as well.
  • Efforts to impede the progress of Alzheimer’s disease have been disappointing, and the drugs currently available to treat the disease address only its symptoms and with limited effectiveness. In comparison to most classes of diseases – from cancer or HIV (human immunodeficiency virus) to cardiovascular and cerebrovascular disease, to osteoporosis to diabetes to mental illness – therapeutic development for Alzheimer’s disease has been, to date, a failure. Lessons can be learned from the successful development of therapeutics for these other chronic illnesses. As one example, a major advance in oncology occurred with the introduction of combination chemotherapy, which has be-come the standard of care for many types of cancer.
  • A second example is the HIV cocktail, first described in 1996. It consists of three drugs, a combination therapy known as HAART (highly active anti-retroviral therapy). Each of the three drugs, in isolation, offered little significant improvement. Medical researcher David Ho and mathematician Alan Perelson reasoned that the three taken together, in the proper ratios, offered an efficacious treatment for HIV, allowing patients to live normal lifespans. HIV infection was transformed from a minimally-treatable disease (similar to the current state of Alzheimer’s disease treatments) to a clearly treatable and chronically-manageable disease with the introduction the combination therapy HAART.


  • Of the more-than-40 ongoing Phase 1, Phase 2, and Phase 3 clinical trials for Alzheimer’s disease, virtually all involve single-therapy approaches. Given the historical precedents, no such approach will likely turn out to be the optimal one for the treatment of Alzheimer’s disease. Complexity is the issue. There are dozens of biological mechanisms, with hundreds of interventions, involved in addressing this disease, and the necessary therapeutics vary by individual and over time.
  • The therapeutics describe the ways to bring these mechanisms into a state they’re enhancing a person’s cognitive health and maintaining control over that health over time and the recommendations change in ratio, over time and by patient. These factors and their complex interrelationships must be personalized based on individual’s specific needs, which calls for a learning, evolving software algorithm. Therapeutics vary based on inputs quantifying a patient’s current health, stage of Alzheimer’s disease progression, current mental capacity, family history, laboratory test results, current medications, allergies, and so on.
  • The protocol is implemented by algorithm in an Internet-based infrastructure. The system also provides seamless networking of data across many different systems and equipment, such as doctor’s offices and hospitals; different medical devices and equipment; and input from caregivers, doctors, and the person themselves.
  • The algorithm includes both pharmacological and non-pharmacological components. For example, if synaptic reconstruction and maintenance form parts of an effective therapy for Alzheimer’s disease, then multiple biological mechanisms may require normalization, enhancement, or administration. Examples of these underlying biological mechanisms include: activating autophagy periodically, blocking prionic tau amplification, increasing beta-amyloid clearance, inhibiting beta-amyloid oligomerization, minimizing inflammation, normalizing neurotrophic factors, reducing ApoE Ɛ4-mediated signals, reducing stress, reducing tau phosphorylation, restoring cholinergic neurotransmission, and reversing memory loss.
  • Assessing the status of these biological mechanisms involves quantifying and observing hormonal balance, C-reactive proteins and other inflammation-related markers, diet (such as avoidance of high-glycemic-index foods and saturated fats), exercise, homocysteine, intermittent fasting, omega-3 acids, sleep and melatonin, stress, targeted antioxidants, and vitamin D3. A consequence of such a therapeutic system approach is that it may allow drug candidates that failed in monotherapeutic clinical trials to demonstrate beneficial effects when used as part of the system.
  • Biological mechanisms related to Alzheimer’s disease have been identified in supporting research by neuroscientists, such as William Jagust at UC Berkeley, Varghese John at the Buck Institute for Re-search on Aging, Murali Doraiswamy at Duke University, and Dale E. Bredesen and Gary Small at UCLA, and described by authors, such as Jean Carper of the New York Times. For any person, each of these biological mechanisms is in a certain state. Some of the states may be “just fine” – that is, measurements related to variables that correspond to a given mechanism lie within the recommended target range for the disease, and nothing is recommended to be changed at this time.
  • Others may be in poor condition, and are thus the most severe and the ones to focus on first. Addressing the dozens of underlying biological mechanisms that lead to fulfilling the goals, that is, bringing the data variables associated with each mechanism into the recommended target range for the disease, is what brings about the reduction and reversal of the effects of Alzheimer’s disease.

COVID-19 Update: COVID-19 For your safety we utilize Telemedicine visits exclusively. Our safely garbed phlebotomist will come to your home and draw blood for labs.